Quantitative hybrid fluorescence and CT to assess drug biodistribution in cancer research

Quantitative hybrid fluorescence and CT to assess drug biodistribution in cancer research

Prof. Fabian Kiessling, RWTH Aachen, Institute of Experimental Molecular Imaging

Fabian Kiessling presents some aspects of their research on optical tomography. For a detailed biodistribution analysis, PET and SPECT are usually preferred as they are more accurate and quantitative, so the question is, can optical imaging become a complementary tool for pre-clinical biodistribution analysis?

The talk took place at the EMIM 2022.


You may also like

Bart Cornelissen imaging DNA damage webinar thumbnail
Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging.
webinar thumnail Marko Rosenholm
Marko Rosenholm presents some of the findings and results regarding dynamic SPECT/CT imaging of a glymphatic system they have acquired with the MILabs VECTor/CT system.
Bruce Hasegawa Memorial Lecture 2021
This annual lecture honors the legacy of Dr. Bruce Hasegawa. MILabs’ Founder and CEO, Prof. Freek Beekman, presents the 2021 Bruce Hasegawa Memorial Lecture at the University of California, San Francisco. In this video presentation, he talks about the physics, engineering, and application of Fully Integrated Ultra-High Definition Optical Tomography, PET, SPECT & X-ray CT.
Scroll to Top